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Nitric Oxide (NO) is an intracellular signalling mediator, which affects many biological processes via 
the posttranslational modification of proteins through S-nitrosation. The availability of NO and NOS-
derived reactive oxygen species (ROS) from enzymatic uncoupling are determined by the NO synthase 
cofactor Tetrahydrobiopterin (BH4). Here, using a global proteomics “biotin-switch” approach, we 
identified components of the ubiquitin-proteasome system to be altered via BH4-dependent NO 
signalling by protein S-nitrosation. We show S-nitrosation of ubiquitin conjugating E2 enzymes, 
in particular the catalytic residue C87 of UBC13/UBE2N, leading to impaired polyubiquitylation by 
interfering with the formation of UBC13~Ub thioester intermediates. In addition, proteasome cleavage 
activity in cells also seems to be altered by S-nitrosation, correlating with the modification of cysteine 
residues within the 19S regulatory particle and catalytic subunits of the 20S complex. Our results 
highlight the widespread impact of BH4 on downstream cellular signalling as evidenced by the effect of 
a perturbed BH4-dependent NO-Redox balance on critical processes within the ubiquitin-proteasome 
system (UPS). These studies thereby uncover a novel aspect of NO associated modulation of cellular 
homeostasis.
Nitric Oxide (NO), produced by endothelial nitric oxide synthase (eNOS), is a key mediator of vascular home-
ostasis, and NO bioavailability is reduced early in vascular disease states such as hypercholesterolemia, diabetes 
and hypertension, as well as throughout the progression of atherosclerosis1–3. This is a result of both decreased 
NO synthesis and increased NO consumption by reactive oxygen species (ROS) such as superoxide. In these dis-
ease states, eNOS may become enzymatically ‘uncoupled’ and generates superoxide rather than NO, contributing 
to vascular oxidative stress and endothelial dysfunction4,5. This switch between NO and ROS production, and the 
subsequent perturbation of NO-Redox balance, is determined by the availability of the essential cofactor tetrahy-
drobiopterin (BH4)6,7. As these redox sensor and effector functions of BH4 expand the repertoire of NOS sig-
nalling to include not only NO, but also ROS, we therefore propose NOS/BH4 as a redox ‘hub’ linking upstream 
redox-sensitive effects of BH4 with redox-dependent targets and pathways that lie downstream8.
NO and ROS signal through chemical reactions with specific atoms of target proteins that lead to modifica-
tion of metal centres and to covalent protein modifications. This notion of NO–Redox balance may be defined 
by the idea that reactive nitrogen species (RNS) and ROS work together in biological systems to achieve optimal 
signalling. NO-Redox imbalance arises when cellular signalling is disrupted by perturbed ROS/RNS. Moreover, 
cross-talk exists between the enzymes that produce ROS and RNS, so NO deficiency can in some cases result in 
increased ROS production. Thus, the interactions between ROS and RNS are multifaceted and strike a balance 
that can be disrupted at both the cell and organ levels in cardiovascular disease states, as within the dysfunctional 
endothelium. A key concept in understanding redox balance in the cardiovascular system is that the effects of 
ROS and RNS depend on the location, amount, and timing of their production.
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NOS is the major source of NO in mammalian cells, and activation of the enzyme following stimulation 
mediates a broad range of signalling pathways. In addition to the classical interaction with haem proteins such as 
sGC, NO exerts physiological actions through the posttranslational modification and regulation of proteins, and 
a large body of evidence now demonstrates that s-nitrosation of Cys residues within a wide spectrum of proteins 
determines the ubiquitous influence of NO on cellular function9,10. For instance, the NO-haem interaction acti-
vates soluble guanylate cyclase (sGC), and in this way stimulates the synthesis of GMP, the subsequent activation 
of protein kinase G and the modulation of phosphorylation-dependent signalling11,12. Furthermore, activation of 
the transcription factor NF-E2-related factor (NRF2) is achieved by inactivation of its cognate ubiquitin E3 ligase 
complex, triggered by S-nitrosation of critical cysteine residues in the Kelch-like ECH-associated protein (Keap1), 
leading to the disassembly of its association with the Cullin 3 ubiquitin E3 ligase complex13–15. Stabilised NRF2 
levels subsequently lead to the induction and activation of antioxidant defence genes. Incomplete understanding 
of the balance among NO, ROS, and downstream redox effects may underlie the inconsistent effects of “antioxi-
dant” therapies, and the ability of NO to modulate such a wide range of signalling pathways allows for the possi-
bility that dysregulated s-nitrosation could contribute to the pathophysiology of an equally wide range of diseases.
We have recently determined that the impact of BH4 on cellular redox signalling in endothelial cells and 
animal models, where abolition of BH4 leads to increased cellular generation of superoxide16–19. Moreover, we 
also demonstrated that a proportion of this superoxide is produced directly from uncoupled eNOS, and that 
BH4 plays an important role in the mitochondria20. While these studies show that the molecular and cellular 
mechanisms through which BH4 exerts its effects on eNOS are now well established, the downstream impact 
of these regulatory mechanisms on eNOS-dependent signalling, and the identification of the resulting target 
proteins remain unknown. The aim of this study was to explore the impact of BH4 deficiency on cellular redox 
balance, and to discover novel proteins and pathways that are altered through BH4-dependent NO signalling by 
S-nitrosation. We uncovered NO modifications on critical components of the ubiquitin-proteasome system with 
possible widespread implications in NO-mediated cellular processes.
Methods
Cell Culture. sEnd.1 murine endothelial cells and Tet-regulatable GCH cells were cultured in DMEM 
(Invitrogen), supplemented with 10% FBS, glutamine (2 mmol/litre), penicillin (100 units/ml), and streptomycin 
(0.1 mg/ml). We used NIH 3T3 murine fibroblasts stably transfected with a tet-off transactivator construct. In the 
presence of doxycycline, binding of the transactivator is blocked, and gene expression is prevented. These initial 
3T3-tet-off cells, previously shown to express neither eNOS nor GTPCH and also confirmed to be devoid of neu-
ronal NOS, inducible NOS, and eNOS protein, were stably transfected with a plasmid encoding hemagglutinin 
(HA) antigen-tagged-human GCH1 under the control of a tetracycline-responsive element, Individual colonies 
were isolated and analyzed for GCH1 expression and a cell line, termed “GCH cells,” was established from expan-
sion of a single colony. GCH cells were stably transfected with a plasmid encoding a human eNOS-eGFP fusion 
protein and clones were picked. All of the cell lines underwent three rounds of clonal selection. GCH cells were 
maintained in medium containing Hygromycin B (200 μg/ml) and Geneticin® (200 μg/ml). NIH 3T3 murine 
fibroblasts were stably transfected with a Tet-Off transactivator construct, as previously described. Doxycycline 
(1 μg/ml) was added to cell culture media to abolish transcription of Gch1 mRNA where appropriate as previously 
described7.
Gch1 Knockdown by RNA Interference. Gch1-specific, ON-TARGETplus SMARTpool siRNA were pur-
chased from Dharmacon Thermo Scientific. The siRNA were used as a pool of four specific siRNA duplexes with the 
following sequences6,7: Duplex 1, GGUAGAAUGCUAAGUACGU; Duplex 2, CGAGAAGUGUGGCUACGUA; 
Duplex 3, GAGAAGGGAGAAUCGCUUU; and Duplex 4, AGUAGUGAUUGAAGCGACA. 24 h prior to trans-
fection, sEnd.1 cells were seeded into 6-well plates. Cells were then transfected with Gch1-specific siRNA (100 
nmol/litre), or nonspecific (NS) pooled duplex negative control siRNA (100 nmol/litre), using DharmaFect1 
transfection reagent (Dharmacon). Cells were cultured for 72 h and gene silencing was detected by analysis of 
GTPCH protein expression by means of Western blotting using GTPCH-specific antibodies.
Biopterin Quantification by HPLC with Electrochemical Detection. BH4, BH2, and biopterin lev-
els in cell and mitochondrial lysates were determined by HPLC followed by electrochemical and fluorescent 
detection, as described previously. Briefly, the cells were grown to confluency and harvested by trypsinisation. 
Mitochondria from confluent T175 flasks were isolated using the Qproteome Mitochondrial Isolation Kit 
(Qiagen). Sample pellets were resuspended in PBS (50 mmol/litre), pH 7.4, containing dithioerythritol (1 mmol/
litre) and EDTA (100 μmol/litre) and subjected to three freeze-thaw cycles. Following centrifugation (15 min 
at 17,000 × g, 4 °C), the samples were transferred to new, cooled microtubes and precipitated with ice-cold 
extraction buffer containing phosphoric acid (1 mol/litre), trichloroacetic acid (2 mol/litre), and dithioerythritol 
(1 mmol/litre). The samples were vigorously mixed and then centrifuged for 15 min at 17,000 × g, 4 °C. The sam-
ples were injected onto an isocratic HPLC system and quantified using sequential electrochemical (Coulochem 
III, ESA Inc.) and fluorescence (Jasco) detection. HPLC separation was performed using a 250 mm, ACE C-18 
column (Hichrom) and mobile phase comprising of sodium acetate (50 mmol/litre), citric acid (5 mmol/litre), 
EDTA (48 μmol/litre), and dithioerythritol (160 μmol/litre) (pH 5.2) (all ultrapure electrochemical HPLC grade), 
at a flow rate of 1.3 ml/min. Background currents of +500 μA and −50 μA were used for the detection of BH4 on 
electrochemical cells E1 and E2, respectively. 7,8-BH2 and biopterin were measured using a Jasco FP2020 fluo-
rescence detector. Quantification of BH4, BH2, and biopterin was made by comparison with authentic external 
standards and normalised to sample protein content7,21.
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Western Blotting. Cell lysates were prepared by homogenisation in ice-cold CelLytic™ M buffer (Sigma) 
containing protease inhibitor cocktail (Roche Applied Science). Lysates were centrifuged at 17,000 × g for 10 min-
utes at 4 °C, and samples were prepared using LDS sample buffer (Invitrogen). Western blotting was carried 
out using standard techniques with anti–GAPDH, –GTPCH, –eNOS, –Rluc8.1, –Rluc8.2, –Ub, –E2N, –E2V1 
antibodies.
The enrichment and detection of protein-SNO by the biotin switch technique. Cysteine-bound 
NO was replaced with biotin using an adaptation of the Biotin Switch technique as described previously22,23. 
Following trypsinolysis, pulled down peptides were then detected using mass spectrometry, and the target pro-
teins by Western blotting using specific antibodies as described below. We detected 543 altered peptides in 477 
proteins, with the requirement that every SNO peptide contained at least one cysteine.
Organomercury capture of SNO proteins. Phenylmercury resin (kindly provided by Professor Harry 
Ischiropoulos and Dr Paschalis Doulias, University of Pennsylvania, USA) was used to capture NO-Cys con-
taining proteins, using mass spectrometry as previously described. Proteins bound to the resin were then eluted 
using Beta-mercaptoethanol and specific target proteins of interest probed by Western blotted using specific 
antibodies24,25.
SNO, Nitrite and Nitrate quantification by NOA. Following preincubation for 1 h in the presence or 
absence of L-monomethylarginine (100 μmol/liter) in Krebs-Henseleit buffer (consisting of 120 mmol/liter NaCl, 
4.7 mmol/liter KCl, 1.2 mmol/liter MgSO4, 1.2 mmol/liter KH2PO4, 2.5 mmol/liter CaCl2, 25 mmol/liter NaHCO3, 
and 5.5 mmol/liter glucose), the cells were exposed to A23187 (1 μmol/liter) for 30 min. Total nitrite and nitrate 
accumulation was measured using the CLD88 NO analyzer (Ecophysics), following published protocols for SNO 
and NOx.
Creation of S-nitrosation Biosensors. Rluc8.1 and 8.2 fragments were PCR-amplified using the rluc8 
plasmid as a template (a gift from Prof. Sanjiv Gambhir, Stanford University)26. The rluc8 PCR fragments were 
cloned into pcDNA3. Gateway destination plasmids were then created by cloning the vector conversion kit 
(Invitrogen) into the rluc8.1 and rluc8.2 vectors, as previously17. For the creation of stable cell lines, this destina-
tion cassette was cloned into the pIRES-puro and Neo plasmids (Clontech). pENTR clones encoding our genes of 
interest were either created by PCR or purchased from Geneservice or Thermo Fisher. To create expression plas-
mids, pENTR clones were recombined with the destination vectors using LR clonase according to the instructions 
of the manufacturer. Recombinant Rluc8 expression plasmids and a LacZ-encoding control plasmid were then 
transfected into sEnd.1 or eNOS/GCH cells and grown on white 96-well plates using FuGENE HD (Roche). Final 
constructs were pExp-Xpo1-Rluc8.1N-pires-puro, and pExp-Rev-Rluc8.2C-pires-neo. We placed our rluc8.1 and 
rluc8.2 halves onto either end of Xpo1 and REV, respectively.
Detection of Biosensor Luminescence by Protein Fragment Complementation Assay. 24 h 
following transfection, cells were treated with drugs as indicated. Cells were then washed with PBS, and 
reconstituted Rluc8 activity was measured using benzyl-coelenterazine (Nanolight) on a BMG Polarstar 
plate reader (5-s read time). Cells were lysed by adding LacZ lysis buffer (120 μM TrisPO4 (pH 7.8), 10 mM 
1,2-cyclohexylenedinitrilotetraacetic acid, 30% glycerol, and 1% Triton X-100) to each well, and LacZ activity was 
measured using ortho-nitrophenyl-β-galactopyranoside. Rluc8 readings were normalized using LacZ activity.
Proteomics analysis. Cell pellets were dissolved in 6 M urea in 50 mM ammonium bicarbonate. 
Dithiothreitol (10 mM) was added and samples were incubated at 60 °C for 45 minutes. Samples were diluted 1:10 
in 50 mM ammonium bicarbonate and sequencing grade modified trypsin (Promega) was added (1:50 w/w) for 
overnight digestion. PMSF (0.5 mM) stopped the reaction and samples were dried down in a vacuum concentra-
tor (Speedvac, Thermo Scientific) and resuspended in acetonitrile (2%) and TFA (0.1%). Samples were desalted 
using ZipTipC18 pipette tips (Millipore), vacuum concentrated and reconstituted in acetonitrile (2%) and TFA 
(0.1%), before mass spectrometric analysis.
Mass spectrometry analysis. Liquid chromatography tandem mass spectrometry (LC-MS/MS) was 
performed using an Orbitrap Velos mass spectrometer, coupled with a Waters nanoAquity UPLC essentially as 
described previously27. In brief, injected samples underwent online desalting using a Trap column Symmetry 
C18, 180 µm × 20 mm, 5 µm particle, Waters). For separation, a BEH C18 column (75 µm × 250 mm, 1.7 µm 
particle, Waters) was used with a flow rate of 250 nl/min over 60 minutes and a gradient of 3–40% acetonitrile 
0.1% Formic acid. Survey scans were acquired in the orbitrap with a resolution of 60,000 at 400 m/z between 300 
and 2000 m/z for up to 100 ms with an ion target of 1E6. Selected precursors were picked above a threshold of 
5E2 counts for MS/MS and excluded for 30 s after sampling. MS/MS spectra were acquired in the ion trap with a 
maximum accumulation time of 100 ms and an ion target of 5E4 counts. CID fragmentation was performed with 
a normalized collision energy of 35. Experiments were conducted in biological triplicates and all sample analysed 
in a single sample batch.
Proteomic data analysis. For label free quantitation raw data were imported into Progenesis QI (Waters) 
with default settings. MS2 spectra were identified with Mascot v 2.4 (Matrix Science) by searching Uniprot/
Swissprot (retrieved 07/09/2012) with taxonomy Mus musculus, using 10ppm and 0.6 Da peptide mass/fragment 
mass tolerances. Allowance was made for 1 missed cleavage site. Biotin-HPDP (C), DeStreak (C), Deamidation 
(N/Q) and Oxidation (M) were set as variable modifications. Data was exported for integration in Progenesis 
with a peptides false discovery rate of 1%. Furthermore, spectra with a peptide score <20 were discarded. Peptide 
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abundances were mean normalised to identified features only. Biotinylated proteins in the Gch1 knockdown 
group were subtracted from those that appeared in the NS group, leaving our group of interest where the appear-
ance of detectable nitrosation was dependent on Gch1 expression and the presence of BH4.
Gene ontology overrepresentation analysis of BH4 enriched proteins. BH4 enriched proteins 
were submitted to PANTHER (version 12) for overrepresentation analysis against the complete Gene Ontology 
biological process, molecular function and cellular component classes. Significantly overrepresented (Bonferroni 
corrected p < 0.05) terms were displayed in the Enrichment Map plugin (version 2.2.1) for Cytoscape (version 
3.5.1) using a Jaccard coefficient of 0.45. Nodes were automatically clustered with the AutoAnnotate plugin 
using MCL clustering with the similarity coefficient used for edge weighting. All single, unconnected nodes were 
removed to create the final enrichment map.
Molecular Modeling of the nitrosation sites of Ubiquitin E2N and 26S proteasome subu-
nits. Figures were produced using PyMOL, using the PDB codes 5AIT, 5L4G and 5L4K.
E2 conjugating enzyme activity assay. E2 activity was assessed using recombinant protein as previously 
described28. Briefly, E1 (0.3 µM), E2N (2.5 µM), E2V1 (2.5 µM) and CHIP (1.0 µM) were mixed in the reaction 
buffer (50 mM Hepes pH 7.6, 100 mM NaCl2 and 5 mM MgCl2) and incubated in the presence of ATP (2 mM) and 
ubiquitin (100 µM) for 1 h at 37 °C. Free ubiquitin chain formation catalysed by CHIP was quantified by Western 
blotting using anti-ubiquitin and anti-CHIP specific antibodies.
Statistical Analysis. Data are expressed as mean ± SEM. Comparisons between NS and GCH siRNA were 
made by the unpaired Student’s t-test. Experiments testing multiple treatments between cell type and knockdown 
were compared by two-way ANOVA, with post-hoc tests applied to test for significance between knockdown and 
treatments, as outlined in the figure legends. P < 0.05 was considered statistically significant.
Results
Gch1 knockdown-induced BH4 deficiency determines NO metabolite accumulation. We first 
tested the effect of targeting Gch1 gene expression, through RNA interference, on the knockdown of GTPCH pro-
tein and examined the subsequent effects on cellular BH4 levels. Transfection of sEnd.1 cells with Gch1-specific 
siRNA lead to a substantial decrease in GTPCH protein, as detected by Western blotting (Fig. 1A). The depletion 
of GTPCH was paralleled by a >90% decrease in cellular BH4 levels (Fig. 1B). This depletion of BH4 was sufficient 
to cause a striking 50% decrease in the accumulation of NOx, and attenuate SNO accumulation significantly 
(Fig. 1C–E). A decreased fraction of S-nitrosated proteins was also detected using the ‘Biotin Switch’ technique 
Figure 1. Depletion of endothelial BH4 results in attenuated accumulation of protein s-nitrosothiols. Exposure 
of sEnd.1 endothelial cells to GCH1-specific siRNA (A) decreases GTPCH protein expression, (B) BH4 levels, 
and (C) markedly attenuates the accumulation of NO metabolites including NOx and s-nitrosothiols (D), and 
NO analyser traces in (E), compared to NS scrambled control siRNA treated cells (*P < 0.05, n = 4/6). Protein 
s-nitrosation is also strikingly diminished in GCH-siRNA vs NS scrambled control cells, as demonstrated using 
the biotin switch technique, compared to HgCl2 treated negative control cells (F), n = 3. Comparable findings 
were shown in an alternative model of BH4 deficiency and eNOS uncoupling, using tet-regulatable eNOS/GCH 
cells in the presence or absence of doxycycline (G–L), *P < 0.05, n = 6–8).
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(Fig. 1F). These data were replicated in a complementary system where GTPCH and BH4 production is attenu-
ated using doxycycline in tetracycline-regulatable cells expressing eNOS (Fig. 1G–L). Importantly, again abolition 
of BH4 lead to a marked decrease in s-nitrosation, demonstrated using biochemical and biotin switch-based 
techniques.
Having shown for the first time that BH4 determines cellular s-nitrosothiol levels and protein s-nitrosation, it 
was important to use an alternative method to overcome the limitations of the ‘biotin switch’ technique. To this 
end, we developed a novel biosensor on the basis of the reconstitution of Renilla luciferase as depicted in Fig. 2, 
as we have previously successfully developed to detect eNOS dimerization17. The SNO biosensor was created 
from the rluc8 construct as described under “Experimental Procedures.” We based the biosensor on the inter-
action of the karyopherin chromosomal region maintenance 1 (CRM1/XPO1) protein with REV, a nucleocyto-
plasmic shuttling HIV protein. This interaction has previously been shown to be dependent on the s-nitrosation 
of XPO1, where XPO1-dependent nuclear export is repressed by NO (Fig. 2A,B). We first characterized the 
biosensor by Western blotting and luminometry. Following transient transfection with either the experimental 
Xpo1- or REV-Rluc fusion constructs or a GST control biosensor, HEK293 cells were shown to express either 
Xpo1-Rluc8.1, REV-Rluc8.2, GST-Rluc8.1, or GST-Rluc8.2, where appropriate, using Rluc8.1- or Rluc8.2-specific 
antibodies (Fig. 2C). We placed our rluc8.1 and rluc8.2 halves onto the C-terminus of either Xpo1 or REV. Cells 
were then transfected with both constructs and luminescence was measured by protein fragment complementa-
tion assay. During the setup and initial characterization of our system, we tested the ability of luciferase to gen-
erate a detectable signal when Xpo1-rluc8.1 and REV-rluc8.2 were co-overexpressed, compared to the negative 
control pairings of Xpo1-Rluc or REV-Rluc with GST-Rluc. Luciferase luminescence was only detectable in cells 
expressing both Xpo1 and REV, or both tagged GST constructs (Fig. 2B). The specificity of the interaction of Xpo1 
and REV was then tested using the NO donor, GSNO, and the specific inhibitor of XPO1, Leptomycin B (LMB). 
Cells were treated with GSNO or LMB for 4 h, and the XPO/REV interaction assessed by luminescence. In cells 
expressing both the Rluc8.1 and Rluc8.2 fusion proteins, a luminescence signal was detectable. Upon exposure 
of the cells to a titration of doses of GSNO, the detectible luminesce signal decreased accordingly; the interaction 
of XPO1 and REV, was decreased by 70% upon exposure of the biosensor to GSNO (1 mM). The same result was 
achieved upon exposure of the biosensor-treated cells with LMB (Fig. 2E). This suggests that GSNO is disrupting 
Figure 2. These changes in SNO signalling are quantifiable using a novel split-renilla based luciferase biosensor. 
A split renilla biosensor was created based on the SNO-dependent interaction of Xpo1 and REV as described 
previously17 (A) Each half of renilla (8.1 and 8.2) was cloned onto the C-terminus of each protein. (B) When a 
critical cysteine in Xpo1 is nitrosated, the Xpo1-REV interaction is abolished. (NES = nuclear export signal). 
(C) Overexpression of the individual proteins, lagged with Rluc8.1 were detected using Western blotting using 
specific antibodies, and (D) Co-overexpression of Xpo1–8.1 and REV-8.2 results in a luminescence signal, as 
detected using a luminescent plate reader, which is significantly greater than that of Xpo1/GST and REV/GST 
negative control overexpression. GST/GST = positive control. (E) This SNO-dependent interaction of XPO1 
and REV responds to a dose response of GSNO and LMB. A decreased signal is observed in the presence of 
either GSNO (0.5–2 mM) or LMB (2.5–15 ng/ml). When these constructs were expressed in either (F) sEnd.1 
endothelial cells in the presence or absence of GCH1-specific siRNA, or (G) eNOS/GCH tet-regulatable cells 
plus doxycycline, an increased interaction was detected indicative of decreased cellular SNO levels. (n = 5/6, 
*P < 0.05).
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the interaction of XPO1 and REV in a NO dependent manner, disassociating the complex to a greater extent as 
the concentration of GSNO increases; the control cells, treated with LMB show the same trend, where binding of 
LMB to the active site cysteine in XPO1 decreased luminescence by 2-fold at 2.5 ng/ml, and approaching 10-fold 
at 15 ng/ml for 30 min. In order to address the impact of BH4 on protein S-nitrosation, we then overexpressed 
the luciferase biosensor in murine endothelial cells concomitant with siRNA that target Gch1. We also expressed 
the biosensor in our tetracycline regulatable eNOS/GCH cell line, and demonstrate that we were able to detect 
a significant increase in luciferase signal, indicative of diminished protein S-nitrosation in both models of BH4 
deficiency (Fig. 2F,G, *P < 0.05, n = 4). These data using this unique biosensor approach further support our 
finding that BH4 level modulates protein-SNO in endothelial cells.
BH4 has wide ranging impact on a range of signalling pathways via protein s-nitrosation. We 
used PANTHER’s overrepresentation analysis to determine the global effects of BH4 deficiency induced by 
knockdown of GTPCH1. S-nitrosylated proteins were captured from cell lysates using the biotin switch method. 
Functional analysis of the SNO proteome (Fig. 3) after BH4 depletion reveals BH4 dependant S-nitrosation in 
a wide range of pathways and cellular compartments. These pathways include both known BH4 functions (e.g. 
redox signalling, mitochondria) and potentially novel pathways such as the ubiquitin-proteasome pathway and 
cell-cell/cell-matrix adhesion. However, it is important to note that although these data demonstrate enriched 
localization of Cys-NO abundance in particular compartments, they do not necessarily imply regulation of those 
proteins by NO modification, without further validation.
Modulation of ubiquitin-proteasome pathway by BH4-dependent s-nitrosation. The proteom-
ics screen for protein s-nitrosation in endothelial cells devoid of BH4 reveals that the enrichment of certain 
cellular compartments such as the mitochondria for the process of s-nitrosation. Moreover, IPA pathway analysis 
identified protein ubiquitination as an enriched pathway that was suggested to be modulated in a BH4- and 
NO-dependent manner, shown in Table 1 and Fig. 4. These findings are striking as they implicate BH4 in a 
number of cellular processes including the regulated and targeted proteasomal degradation of substrate proteins. 
In order to validate, and further advance this pathway analysis result, we focused on the individual members of 
the ubiquitination pathway, using the biotin switch technique. Important controls confirm the specifity of the 
assay for Cys-NO (Fig. 5A,B), and mass spectrometry analysis revealed that several members of the pathway 
were s-nitrosated at various cysteines (Fig. 5C). Four of these peptides (all E2 enzymes), were discovered to be 
nitrosated within the proteins active site, specifically on the catalytic cysteine. The potential impact of these mod-
ifications is summarized in the schematics for the E2 conjugating enzymes, and proteasome, outlined in Fig. 4.
Figure 3. Functional analysis of the BH4-dependant s-nitrosoproteome reveals that the impact of BH4 on 
cellular signalling by NO is widespread. (A) Enrichment map for proteins differentially S-nitrosylated after BH4 
depletion. Nodes represent single gene ontology terms, their size being proportional to the number of proteins 
contained. Nodes that contain similar proteins are joined by edges. Connected nodes were grouped into clusters 
using the MCL clustering algorithm. (B) Summary of the enrichment map in A, where clusters of nodes have 
been collapsed. Terms with known BH4 involvement are highlighted with dashed lines.
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We hypothesized that modification by NO at these sites would potentially have striking effects on their 
function. Within this pathway, we were particularly interested in Ubiquitin conjugating enzyme E2N, where 
the BH4-dependent nitrosation occurred at cysteine 87 (Fig. 5C). Pulldown of SNO proteins using the Biotin 
Switch technique, followed by Western blotting using an anti-biotin antibody revealed that s-nitrosation of 
E2N was present in endothelial cell lysates, and that this nitrosation was elevated after exposure of the lysate to 
GSNO, along with eNOS, GAPDH and E2V1. Pre-reduction with DTT attenuated the abundance of SNO-E2N. 
(Fig. 5E). Confirmation of E2N as a target for modification by NO, and its subsequent modulation by BH4 was 
also demonstrated using the complementary technique of organomercury resin assisted capture and Western 
blotting. Importantly, HgCl2 pretreatment of cell lysates demonstrated the specificity of the assay for Cys-NO 
and S-nitrosation of E2N was clearly detectable in control cells. This specific modification of E2N protein by NO 
was attenuated in cells that produce less NO, due to the knockdown of GTPCH by siRNA (Fig. 5G). This modi-
fication occurred independently of a change in total protein level, and was shown to be in the active site pocket 
highlighted in Fig. 5H.
Having identified new BH4-dependent pathways and a potential role for BH4 in protein ubiquitination, our 
next aim was to establish whether s-nitrosation of Cys87 did indeed alter the function of E2N. Addressing the 
activity of individual ubiquitin enzymes in cell culture systems is not possible, so to alleviate this limitation, we 
used a recombinant protein activity assay. This E2 activity assay was based on the formation of free ubiquitin 
chains, catalysed by CHIP, where E1, CHIP, E2V1 and E2N proteins were combined, incubated for 1 h and ubiq-
uitination was detected by Western blotting using an anti-ubiquitin antibody, as outlined in the Experimental 
Procedures. The activity assay was carried out in the presence of either GSNO or BH4 to mimic the effect of 
s-nitrosation, and to compare the effects of NO donation by GSNO and rule out any unexpected effect of a direct 
action of BH4 itself. Ubiquitination was detected, when all proteins where incubated in the presence of ATP. 
Ubiquitination was not detected when any single protein, or ATP was not included (Fig. 5F). Ubiquitination was 
dose-dependently decreased when GSNO was added, with ubiquitination almost abolished following exposure 
to GSNO (1 mM). In contrast, the enzyme activity assay remained unaltered when BH4, rather than GSNO was 
included, suggesting that the effects of BH4 on protein function are mediated through NO, not by direct modula-
tion of E2 activity by BH4. Importantly, the impact of GSNO on polyubiquitination occurred independent of any 
changes in E1-E2N thio-ester formation (Supplemental Fig. 1), which would support the lack of E1 modification 
by NO in our mass spectrometery dataset.
It was also found that the proteasome pathway was significantly altered in a BH4 dependent manner. Indeed, 
the proteasome subunits are a significant part of the pathway shown in Fig. 4. Mass spectrometry analysis revealed 
S-nitrosation of cysteine residues within proteasomal subunits (PSMC, PSMD, and catalytic subunits PSMA4 and 
PSMB2) (Fig. 6A). This is consistent with what has been observed in vascular smooth muscle cells that were 
directly treated with NO29. To test the functional impact of this finding, we used a fluorescent assay to measure 
the three classical activities of the complex. Indeed, exposure of sEnd.1 endothelial cells to GCH-specific siRNA 
resulted in significant attenuation of chymotrypsin-, trypsin-, and caspase-like activities (Fig. 6B). We then used 
a PyMol molecular modelling approach to gain some insight into the mechanism by which modification by NO 
would lead to the inhibition of proteasome activity (Fig. 6C–E). In the case of PSMB2, we examined the location 
Canonical Pathways
−log 
(p-value) Ratio
Protein Ubiquitination Pathway 11.1 0.11
EIF2 Signaling 11 0.118
Signaling by Rho Family GTPases 9.91 0.105
RhoGDI Signaling 7.7 0.11
Cardiac Hypertrophy Signaling 3.93 0.0681
Chemokine Signaling 3.66 0.113
Endothelin-1 Signaling 3.39 0.0695
Mitochondrial Dysfunction 3.21 0.0702
Hypoxia Signaling in the Cardiovascular System 3.14 0.108
Tight Junction Signaling 2.76 0.0659
TCA Cycle II (Eukaryotic) 2.76 0.174
Wnt/β-catenin Signaling 2.72 0.0651
Glutathione Redox Reactions II 2.51 0.5
Proline Biosynthesis I 2.51 0.5
NF-κB Signaling 2.51 0.0611
Tetrahydrofolate Salvage from 
5,10-methenyltetrahydrofolate 2.3 0.4
NRF2-mediated Oxidative Stress Response 2.28 0.057
VEGF Signaling 2.01 0.068
eNOS Signaling 2.01 0.0581
Oxidative Phosphorylation 1.88 0.0642
Table 1. Qiagen Ingenuity Pathway Analysis identifies several pathways to be enriched, when comparing those 
hits detected in BH4 replete, verses deplete endothelial cells.
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of these BH4-dependent NO-Cys residues relative to the catalytic N-terminal Thr residue (Fig. 6F–H), and show 
that in the catalytic beta subunit PSMB2, NO-Cys163 is to distal from N-Thr53/78 to allow direct interaction 
with NO, therefore suggesting that inhibition of catalysis appears to happen in an indirect fashion. In addition, a 
number of NO-Cys-modifications have also been detected in the regulatory ATP (PSMD1, PSMC2, PSMC6) and 
non-ATP subunits (PSMD2, 6, 11, 12), providing the basis for further potential modulation of function (Fig. 6).
Taken together, these data demonstrate for the first time that the impact of BH4 is far wider than originally 
anticipated, and that BH4 via s-nitrosation of target proteins, can dictate the function of downstream cellular 
pathways, not previously linked with BH4 or NO.
Discussion
In this study, we reveal the impact of altered BH4 production on the redox effector functions of the eNOS/BH4 
redox ‘hub’. We demonstrate that altering BH4 level alone is sufficient to perturb the production of NO and sub-
sequent protein SNO formation, and use a combined proteomic and novel biosensor approach, (with validation 
by organomercury enrichment) to show for the first time that this change in BH4 can have a drastic influence on 
the identification and magnitude of downstream posttranslational signalling by S-nitrosation. We then probed 
one of the most significantly altered pathways identified from the proteomics gene ontology data analysis, that of 
protein ubiquitination, and used a biochemical approach to validate the effect of BH4-dependent s-nitrosation on 
its activity, implied by the unbiased proteomics screen, and corroborated by two different methods. Furthermore, 
we show that SNO modification of a critical cysteine residue in a candidate E2 conjugating enzyme does indeed 
interfere with its function, along with reducing the activity of the proteasome. This study clearly demonstrates the 
importance of BH4 as a modulator of redox signalling and indicates that BH4 and eNOS, acting as a signalling 
‘hub’ may modulate a plethora of new biochemical pathways.
The idea that modification of protein function by nitrosation is involved in cardiovascular homeostasis and 
disease is not novel, however the notion that BH4 availability determines ubiquitous downstream signalling via 
Figure 4. BH4 modulates the nitrosation of key proteins in the Ubiquitin-Proteasome system. (A) Qiagen 
ingenuity pathways analysis (IPA) uncovers ‘protein ubiquitination’ and (B) the ‘26S Proteasome’ as the top 
pathway demonstrated to be altered in a BH4- and NO-dependent manner, with specific targets highlighted 
in Blue. (C) Specific NO targets (E2N, E2D3 and E2E1) within the E2 conjugating enzymes are illustrated in 
schematic form. (D) IPA analysis also suggests that BH4-dependent modification by NO is important to the 
function of the proteasome multi-catalytic complex (the 20S core and 19S regulatory particle), and all modified 
subunits are depicted in the schematic.
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this posttranslational mechanism has not been addressed until now. Having been proven to occur in a plethora 
of proteins with roles in cardiovascular homeostasis, nitrosation now explains the wide range of cellular effects of 
NO. For example, nitrosation of HIF-1 alpha increases VEGF production and myocardial capillary density in the 
heart, while addition of NO to a critical cysteine in Caspase 3 opposes apoptosis and preserves endothelial func-
tion. In separate experiments, BH4 has also been widely implicated to have similar roles, being required for the 
effects of VEGF, and having antiapoptotic functions in the endothelium30–32. In addition, aberrant S-nitrosation 
is common in cardiovascular disease and can at least in part explain the dysfunctional actions of the ryanodine 
receptor in cardiac arrythmogenesis33,34 as well as in pulmonary hypertension35. In both of these conditions, as 
well as many others, supplementation of BH4 has been shown to be beneficial in animal models, predominantly 
through restoring NO production and normal NO signalling.
The subcellular compartment absolutely determines the targets of redox signalling, along with the type and 
source of the signalling moiety. Interestingly, our data expose the mitochondria as a key subcellular compart-
ment where BH4-dependent nitrosation takes place, highlighted in Table 1, and also presented in Fig. 3. This is 
consistent with the large proportion of mitochondrial proteins known to be modulated by NO; such as complex 
I, where deactivation by NO slows the reactivation of mitochondria during the crucial first minutes of the reper-
fusion of ischemic tissue, thereby decreasing ROS production, oxidative damage and tissue necrosis. Our recent 
report studying the ‘non-canonical’ roles for BH4 was the first to suggest that BH4 dictates redox balance in the 
mitochondria. Specifically, BH4 depletion resulted in striking production of ROS from the mitochondria, changes 
in antioxidant protein expression, and marked alterations of the cellular proteome and metabolome signature of 
the endothelial cell in the absence of BH4. These changes in cellular biochemistry, metabolism and the changes 
in posttranslational signalling presented here, underlie the importance of BH4 as a regulator of cellular function.
Figure 5. E2N is a target for BH4-dependent signalling via NO. BH4 deficiency alters NO/Redox balance and 
subsequent pottranslational modification of targets by NO. (A) Important controls are shown, validating the 
specificyt of the biotin switch for Cys-NO, where detectable signal is significantly attenuated in the absence of 
ascorbate, and following pre-reduction by exposure to UV and DTT. (B) Decreased abundance of nitrosated 
proteins are detected in GCH- vs Non-specific siRNA treated endothelial cells. (C) Cysteine residues within 
E2 conjugating enzymes are profoundly modified, and a significant number of those cysteine-containing 
peptides are catalytic cysteines that would be predicted to modify protein activity, and these changes occur 
independently of changes in total E2N protein shown by Western blotting using a E2N–specific antibody 
(D). (E) Protein lysates underwent the biotin switch procedure following exposure to either GSNO or GSNO 
and DTT. Detection of biotin-Cys using specific antibodies following pull down, clearly demonstrates that 
E2N is susceptible to nitrosation. (F) A complimentary method where SNO proteins are captured using 
organomercury supports the biotin switch findings was used to support the biotin switch findings; pre-
exposure to HgCl2 abolished detectable SNO protein, and (G) E2N is clearly detectable in NS, but is markedly 
decreased in GCH-specific siRNA treated endothelial cells. (H) Using molecular modelling of the Cys87-NO 
in E2N by PYMol, it can be seen that Cys87 is exposed in a binding pocket (shown in Green). (I) The effect of 
nitrosation on the activity of E2N was studied using a recombinant protein activity assay. Recombinant proteins 
were incubated in the presence or absence of GSNO and BH4, as described in the Experimental Procedures. 
Polyubiquitination was only detected in the presence of all components of the assay, and did not occur when any 
one protein or substrate was omitted. The activity of E2N was inhibited by GSNO in a dose-dependent manner, 
and remained unchanged when exposed to BH4, thus demonstrating that the effects of BH4 are NO dependent, 
and not through unexpected direct effects of BH4 on protein activity (n = 3).
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The aim of this study was to uncover new mechanisms in which BH4 may play a role, helping us understand 
the wider effects of BH4, and elucidating new mechanisms we can exploit in the design of future drug treatments. 
To this end, the most prominent finding from the unbiased proteomics screen in these data was the requirement 
of the ubiquitin-proteasome system for BH4. Indeed, Ingenuity Pathway Analysis exposed this pathway as the 
most altered by BH4-dependent nitrosation, as detected using both the biotin switch and organomercury capture 
techniques. Importantly, BH4 is also a critical cofactor for the aromatic amino acid hydroxylase enzymes such 
as phenylalanine and tyrosine hydroxylase, and therefore BH4 plays important roles in the synthesis of neuro-
transmitters such as dopamine and noradrenaline. The data presented in this study would suggest that effects of 
BH4 insufficiency on protein s-nitrosation of key enzymes within the ubiquitin proteasome pathway occur in an 
NO-dependent manner, independent of these other cofactor roles.
Ubiquitination is an enzymatic posttranslational modification process that occurs on proteins based on the 
ligation of ubiquitin (an 8.5 kDa protein) on a target protein lysine residues. This covalent attachment of ubiquitin 
Figure 6. BH4 positively regulates the activity of the proteasome. Posttranslational modification of proteasome 
targets by NO. (A) Cysteine residues within subunits of the 26S proteasome are profoundly modified in a BH4 
dependent manner. (B–D) PSMC6, RPN2 and RPN5 subunits are all demonstrated to be altered at specific sites, 
where the Cys side chains are shown in green. Human models have been presented. (E) sEnd.1 endothelial cells 
were exposed to GCH-specific, or NS control siRNA, and proteasome activity was assessed using a Promega 
proteasome activity assay as in the Experimental Procedures. Knockdown of BH4 levels, and subsequent NO/
redox imbalance using siRNA, significantly inhibited proteasome activity (n = 4, *P < 0.05). (F) Nitrosation 
sites in PSMB2 (shown in Green) are only visible upon processing of the protein where cleavage at 53Thr and 
78Thr occurs during proteasome maturation as shown in red and blue, respectively (G,H).
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on lysine residues requires the coordinated reaction of three enzymes: E1 enzyme, which promote ubiquitin 
adenylation required for its covalent binding to the cysteine residue located at the E1 active site; E2 (ubiquitin 
conjugating enzymes) that accept ubiquitin from the ubiquitin ‘loaded’ E1; and E3 ubiquitin ligases that are 
required for target recognition and final transfer the ubiquitin to the protein for targeted for degradation. Protein 
ubiquitination is therefore central to the mechanism underlying protein turnover and quality control, as it is 
responsible for the redirection of damaged/unfolded proteins towards the proteasome to be degraded. It is now 
commonly accepted that ubiquitination also plays critical roles in the turnover of aged organelles, and cellular 
processes and signalling which include antigen processing, apoptosis, cell cycle, DNA transcription, and repair. 
The specificity of the Ubiquitin-proteasome system is dictated by the E3 protein, which selects the substrate, and 
there are hundreds of E3 ligases. Our data presented herein suggests that BH4 is central to the activity of E2 con-
jugating enzymes as exemplified by our discovery that Cys87 on Ubc13 is modified and most likely interferes with 
the formation of ubiquitin thioester intermediates before the transfer to the cognate E3 ubiquitin ligase (Fig. 5C). 
This implies that BH4 may subsequently be important in the wide range of pathways that contain the proteins tar-
geted for K63-polyubiquitylation that may be regulated by NO. If we hypothesize that one E2 conjugating enzyme 
controls the passing of ubiquitin from multiple E3 ligases, each to multiple target proteins, then the potential 
impact for regulation of the ubiquitin-proteasome system by BH4 is vast.
Beside the effects on ubiquitin conjugating system, NO has been shown to directly interfere with the activ-
ity of the proteasome complex. Our data demonstrating that BH4-dependent nitrosation affects proteasome 
catalytic activity is supported by reports in vascular smooth muscle cells where S-nitrosoglutathione (GSNO) 
exposure provokes nitrosation of residues within the 20S catalytic core of the 26S proteasome, known to con-
tain 10 cysteines, which subsequently results in the inhibition of all three catalytic activities of the complex 
(chymotrypsin-, trypsin-, and caspase-like)29. Consistent with this, we observe S-nitrosation on cysteine residues 
encoded by proteasomal subunits within the 20S core as well as the 19S regulatory complex (Fig. 6B–D). Since 
cysteines are not directly involved in the catalytic mechanism of proteolysis, the effect of cysteine modification 
on enzymatic activity is most likely going to be indirect. NO-Cys-modifications have also been noted in the reg-
ulatory ATP (PSMD1, PSMC2, PSMC6) and non-ATP subunits (PSMD2, 6, 11, 12), suggesting potential alter-
ations in substrate recognition and unfolding (Fig. 6). Modifications on regulatory subunits and core particle of 
the proteasome have been reported – General oxidation36 and Cys-glutathionylation interfere with proteasomal 
proteolysis37. Thioredoxin-related protein TNXL1 is part of the proteasome complex38 and may reverse unwanted 
Cys-modifications.
There are many reports that link the ubiquitin-proteasome system with the regulation of cardiovascular func-
tion, in both the heart and vessels. Cardiac hypertrophy, characterized by cell enlargement rather than prolifera-
tion, exhibits increased protein degradation by the ubiquitin-proteasome system, and dysfunctional proteasome 
function has been observed in heart failure, evidenced by the accumulation of ubiquitin-positive aggregates in 
failing hearts39 as well as levels of PA28 regulatory components40 Also, S-nitrosation of protein substrates can 
trigger degradation via the ubiquitin proteasome system, as has been shown for CDK541, PDE542 and caspase-343.
In summary, our global profiling approach revealed widespread BH4-dependent S-nitrosation across the pro-
teome affecting prominent enzymes within the UPS. This opens up possibilities of targeting BH4-dependent 
redox signalling to intervene in cardiovascular disease as a viable therapeutic strategy.
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